HRTX - Heron Therapeutics launches ZYNRELEF in the U.S.

Heron Therapeutics (HRTX) announces that ZYNRELEF (bupivacaine and meloxicam) extended-release solution, is now commercially available at all national wholesalers and the largest specialty distributors in the United States.Shares up more than 7% premarket.ZYNRELEF was approved by the U.S. FDA for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty, in May.

For further details see:

Heron Therapeutics launches ZYNRELEF in the U.S.